Cargando…
Adrenomedullin Therapy in Moderate to Severe COVID-19
The 2019 coronavirus (COVID-19) pandemic is still in progress, and a significant number of patients have presented with severe illness. Recently introduced vaccines, antiviral medicines, and antibody formulations can suppress COVID-19 symptoms and decrease the number of patients exhibiting severe di...
Autores principales: | Kita, Toshihiro, Kitamura, Kazuo |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8945653/ https://www.ncbi.nlm.nih.gov/pubmed/35327335 http://dx.doi.org/10.3390/biomedicines10030533 |
Ejemplares similares
-
Translational studies of adrenomedullin and related peptides regarding cardiovascular diseases
por: Kita, Toshihiro, et al.
Publicado: (2022) -
Adrenomedullin: A Novel Therapeutic for the Treatment of Inflammatory Bowel Disease
por: Ashizuka, Shinya, et al.
Publicado: (2021) -
Adrenomedullin Therapy in Patients with Refractory Ulcerative Colitis: A Case Series
por: Ashizuka, Shinya, et al.
Publicado: (2015) -
Adrenomedullin: A Novel Therapy for Intractable Crohn's Disease with a Loss of Response to Infliximab
por: Ashizuka, Shinya, et al.
Publicado: (2019) -
Safety, Tolerability, and Pharmacokinetics of Adrenomedullin in Healthy Males: A Randomized, Double-Blind, Phase 1 Clinical Trial
por: Kita, Toshihiro, et al.
Publicado: (2020)